Loading…

11β-Hydroxysteroid Dehydrogenase Type II Inhibition Causes Cerebrovascular Remodeling and Increases Infarct Size after Cerebral Ischemia

Direct mineralocorticoid receptor (MR) activation with deoxycorticosterone acetate has deleterious effects on the cerebral vasculature. Inhibition of 11β-hydroxysteroid dehydrogenase type II (11βHSD2) mimics the detrimental effects of elevated mineralocorticoids in the heart, but the effect of enzym...

Full description

Saved in:
Bibliographic Details
Published in:Endocrinology (Philadelphia) 2009-02, Vol.150 (2), p.713-719
Main Authors: Osmond, Jessica M, Dorrance, Anne M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c392t-47eeb4f550c3642af0881d1befeb1b27d943c49474599c92327ccd29203b3acd3
cites cdi_FETCH-LOGICAL-c392t-47eeb4f550c3642af0881d1befeb1b27d943c49474599c92327ccd29203b3acd3
container_end_page 719
container_issue 2
container_start_page 713
container_title Endocrinology (Philadelphia)
container_volume 150
creator Osmond, Jessica M
Dorrance, Anne M
description Direct mineralocorticoid receptor (MR) activation with deoxycorticosterone acetate has deleterious effects on the cerebral vasculature. Inhibition of 11β-hydroxysteroid dehydrogenase type II (11βHSD2) mimics the detrimental effects of elevated mineralocorticoids in the heart, but the effect of enzyme inactivation on the cerebral vasculature is unknown. Therefore, we hypothesized that systemic 11βHSD2 inhibition with carbenoxolone (CBX) would cause remodeling of the middle cerebral artery (MCA) and increase the damage caused by cerebral ischemia. Six-week-old male Sprague Dawley rats were divided into control and CBX (2.5 mg/d) + 0.9% NaCl treated. After 4 wk treatment, rats were used to assess either structure and reactivity of the MCA or the response to cerebral ischemia using the MCA occlusion technique. Cerebral damage was assessed by 2,3,5-triphenyltetrazolium chloride staining and expressed as a percentage of the hemisphere infarcted. CBX treatment increased systolic blood pressure (153.2 ± 7.3 vs. 122.1 ± 4.4 mm Hg; P < 0.05) compared with control rats. MCAs from CBX treated rats were smaller and stiffer than control MCAs over a range of intralumenal pressures, indicating inward remodeling of the vessel. CBX treatment significantly increased ischemic cerebral infarct size compared with control rats (27.1 ± 5.4% vs. 14.8 ± 4.2%; P < 0.05). These data indicate that inhibition of 11βHSD2, and, thus, disproportionate glucocorticoid activation of the MR, results in remodeling of the MCA and worsens the outcome of cerebral ischemia, further underscoring the importance of understanding the mechanism by which MR activation leads to cerebrovascular disease. 11β-Hydroxysteroid dehydrogenase inhibition increases blood pressure, altering cerebral vessel structure in a manner that increases the damaged caused by focal cerebral ischemia in rats.
doi_str_mv 10.1210/en.2008-0808
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2646544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1210/en.2008-0808</oup_id><sourcerecordid>3130598664</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-47eeb4f550c3642af0881d1befeb1b27d943c49474599c92327ccd29203b3acd3</originalsourceid><addsrcrecordid>eNp1kd-K1DAYxYMo7jh65wMERLyxa_61aW8EGf9sYUHQ9TqkydeZLJ1kTNrF2TfY1_FBfCZTpqwIehWS_M75Dt9B6Dkl55RR8gb8OSOkLkhN6gdoRRtRFpJK8hCtCKG8kIzJM_Qkpet8FULwx-iM1rUoK1Gu0B2lv34WF0cbw49jGiEGZ_F72M0PW_A6Ab46HgC3LW79znVudMHjjZ4SJLyBCF0MNzqZadARf4F9sDA4v8Xa2ywwEfQMtr7X0Yz4q7sFrPs8ZtHqAbfJ7GDv9FP0qNdDgmfLuUbfPn642lwUl58_tZt3l4XhDRsLIQE60ZclMbwSTPekrqmlHfTQ0Y5J2whuRCOkKJvGNIwzaYxlDSO849pYvkZvT76HqduDNeDHHEMdotvreFRBO_X3j3c7tQ03ilWiKvP-1ujFYhDD9wnSqK7DFH3OrDjlpGzqqpqp1yfKxJBShP5-AiVqLk6BV3Nxai4u4y8X07xMPfRRe-PSvSbzleSSZO7ViQvT4X-OxeLITyR4G0x0Hg4RUvoT9p85fgMi07ce</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130598664</pqid></control><display><type>article</type><title>11β-Hydroxysteroid Dehydrogenase Type II Inhibition Causes Cerebrovascular Remodeling and Increases Infarct Size after Cerebral Ischemia</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>Osmond, Jessica M ; Dorrance, Anne M</creator><creatorcontrib>Osmond, Jessica M ; Dorrance, Anne M</creatorcontrib><description>Direct mineralocorticoid receptor (MR) activation with deoxycorticosterone acetate has deleterious effects on the cerebral vasculature. Inhibition of 11β-hydroxysteroid dehydrogenase type II (11βHSD2) mimics the detrimental effects of elevated mineralocorticoids in the heart, but the effect of enzyme inactivation on the cerebral vasculature is unknown. Therefore, we hypothesized that systemic 11βHSD2 inhibition with carbenoxolone (CBX) would cause remodeling of the middle cerebral artery (MCA) and increase the damage caused by cerebral ischemia. Six-week-old male Sprague Dawley rats were divided into control and CBX (2.5 mg/d) + 0.9% NaCl treated. After 4 wk treatment, rats were used to assess either structure and reactivity of the MCA or the response to cerebral ischemia using the MCA occlusion technique. Cerebral damage was assessed by 2,3,5-triphenyltetrazolium chloride staining and expressed as a percentage of the hemisphere infarcted. CBX treatment increased systolic blood pressure (153.2 ± 7.3 vs. 122.1 ± 4.4 mm Hg; P &lt; 0.05) compared with control rats. MCAs from CBX treated rats were smaller and stiffer than control MCAs over a range of intralumenal pressures, indicating inward remodeling of the vessel. CBX treatment significantly increased ischemic cerebral infarct size compared with control rats (27.1 ± 5.4% vs. 14.8 ± 4.2%; P &lt; 0.05). These data indicate that inhibition of 11βHSD2, and, thus, disproportionate glucocorticoid activation of the MR, results in remodeling of the MCA and worsens the outcome of cerebral ischemia, further underscoring the importance of understanding the mechanism by which MR activation leads to cerebrovascular disease. 11β-Hydroxysteroid dehydrogenase inhibition increases blood pressure, altering cerebral vessel structure in a manner that increases the damaged caused by focal cerebral ischemia in rats.</description><identifier>ISSN: 0013-7227</identifier><identifier>EISSN: 1945-7170</identifier><identifier>DOI: 10.1210/en.2008-0808</identifier><identifier>PMID: 18845645</identifier><identifier>CODEN: ENDOAO</identifier><language>eng</language><publisher>Chevy Chase, MD: Endocrine Society</publisher><subject>11β-Hydroxysteroid dehydrogenase ; Acetic acid ; Biological and medical sciences ; Blood pressure ; Cerebral blood flow ; Cerebral infarction ; Cerebrovascular diseases ; Cerebrum ; Damage assessment ; Dehydrogenase ; Dehydrogenases ; Fundamental and applied biological sciences. Psychology ; Glucocorticoids ; Hydroxysteroids ; Inactivation ; Ischemia ; Medical sciences ; Mineralocorticoid receptors ; Neurology ; Occlusion ; Sodium chloride ; Triphenyltetrazolium chloride ; Vascular diseases and vascular malformations of the nervous system ; Vertebrates: endocrinology</subject><ispartof>Endocrinology (Philadelphia), 2009-02, Vol.150 (2), p.713-719</ispartof><rights>Copyright © 2009 by The Endocrine Society 2009</rights><rights>2009 INIST-CNRS</rights><rights>Copyright © 2009 by The Endocrine Society</rights><rights>Copyright © 2009 by The Endocrine Society 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-47eeb4f550c3642af0881d1befeb1b27d943c49474599c92327ccd29203b3acd3</citedby><cites>FETCH-LOGICAL-c392t-47eeb4f550c3642af0881d1befeb1b27d943c49474599c92327ccd29203b3acd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21067370$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Osmond, Jessica M</creatorcontrib><creatorcontrib>Dorrance, Anne M</creatorcontrib><title>11β-Hydroxysteroid Dehydrogenase Type II Inhibition Causes Cerebrovascular Remodeling and Increases Infarct Size after Cerebral Ischemia</title><title>Endocrinology (Philadelphia)</title><description>Direct mineralocorticoid receptor (MR) activation with deoxycorticosterone acetate has deleterious effects on the cerebral vasculature. Inhibition of 11β-hydroxysteroid dehydrogenase type II (11βHSD2) mimics the detrimental effects of elevated mineralocorticoids in the heart, but the effect of enzyme inactivation on the cerebral vasculature is unknown. Therefore, we hypothesized that systemic 11βHSD2 inhibition with carbenoxolone (CBX) would cause remodeling of the middle cerebral artery (MCA) and increase the damage caused by cerebral ischemia. Six-week-old male Sprague Dawley rats were divided into control and CBX (2.5 mg/d) + 0.9% NaCl treated. After 4 wk treatment, rats were used to assess either structure and reactivity of the MCA or the response to cerebral ischemia using the MCA occlusion technique. Cerebral damage was assessed by 2,3,5-triphenyltetrazolium chloride staining and expressed as a percentage of the hemisphere infarcted. CBX treatment increased systolic blood pressure (153.2 ± 7.3 vs. 122.1 ± 4.4 mm Hg; P &lt; 0.05) compared with control rats. MCAs from CBX treated rats were smaller and stiffer than control MCAs over a range of intralumenal pressures, indicating inward remodeling of the vessel. CBX treatment significantly increased ischemic cerebral infarct size compared with control rats (27.1 ± 5.4% vs. 14.8 ± 4.2%; P &lt; 0.05). These data indicate that inhibition of 11βHSD2, and, thus, disproportionate glucocorticoid activation of the MR, results in remodeling of the MCA and worsens the outcome of cerebral ischemia, further underscoring the importance of understanding the mechanism by which MR activation leads to cerebrovascular disease. 11β-Hydroxysteroid dehydrogenase inhibition increases blood pressure, altering cerebral vessel structure in a manner that increases the damaged caused by focal cerebral ischemia in rats.</description><subject>11β-Hydroxysteroid dehydrogenase</subject><subject>Acetic acid</subject><subject>Biological and medical sciences</subject><subject>Blood pressure</subject><subject>Cerebral blood flow</subject><subject>Cerebral infarction</subject><subject>Cerebrovascular diseases</subject><subject>Cerebrum</subject><subject>Damage assessment</subject><subject>Dehydrogenase</subject><subject>Dehydrogenases</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glucocorticoids</subject><subject>Hydroxysteroids</subject><subject>Inactivation</subject><subject>Ischemia</subject><subject>Medical sciences</subject><subject>Mineralocorticoid receptors</subject><subject>Neurology</subject><subject>Occlusion</subject><subject>Sodium chloride</subject><subject>Triphenyltetrazolium chloride</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><subject>Vertebrates: endocrinology</subject><issn>0013-7227</issn><issn>1945-7170</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp1kd-K1DAYxYMo7jh65wMERLyxa_61aW8EGf9sYUHQ9TqkydeZLJ1kTNrF2TfY1_FBfCZTpqwIehWS_M75Dt9B6Dkl55RR8gb8OSOkLkhN6gdoRRtRFpJK8hCtCKG8kIzJM_Qkpet8FULwx-iM1rUoK1Gu0B2lv34WF0cbw49jGiEGZ_F72M0PW_A6Ab46HgC3LW79znVudMHjjZ4SJLyBCF0MNzqZadARf4F9sDA4v8Xa2ywwEfQMtr7X0Yz4q7sFrPs8ZtHqAbfJ7GDv9FP0qNdDgmfLuUbfPn642lwUl58_tZt3l4XhDRsLIQE60ZclMbwSTPekrqmlHfTQ0Y5J2whuRCOkKJvGNIwzaYxlDSO849pYvkZvT76HqduDNeDHHEMdotvreFRBO_X3j3c7tQ03ilWiKvP-1ujFYhDD9wnSqK7DFH3OrDjlpGzqqpqp1yfKxJBShP5-AiVqLk6BV3Nxai4u4y8X07xMPfRRe-PSvSbzleSSZO7ViQvT4X-OxeLITyR4G0x0Hg4RUvoT9p85fgMi07ce</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>Osmond, Jessica M</creator><creator>Dorrance, Anne M</creator><general>Endocrine Society</general><general>Oxford University Press</general><general>The Endocrine Society</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20090201</creationdate><title>11β-Hydroxysteroid Dehydrogenase Type II Inhibition Causes Cerebrovascular Remodeling and Increases Infarct Size after Cerebral Ischemia</title><author>Osmond, Jessica M ; Dorrance, Anne M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-47eeb4f550c3642af0881d1befeb1b27d943c49474599c92327ccd29203b3acd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>11β-Hydroxysteroid dehydrogenase</topic><topic>Acetic acid</topic><topic>Biological and medical sciences</topic><topic>Blood pressure</topic><topic>Cerebral blood flow</topic><topic>Cerebral infarction</topic><topic>Cerebrovascular diseases</topic><topic>Cerebrum</topic><topic>Damage assessment</topic><topic>Dehydrogenase</topic><topic>Dehydrogenases</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glucocorticoids</topic><topic>Hydroxysteroids</topic><topic>Inactivation</topic><topic>Ischemia</topic><topic>Medical sciences</topic><topic>Mineralocorticoid receptors</topic><topic>Neurology</topic><topic>Occlusion</topic><topic>Sodium chloride</topic><topic>Triphenyltetrazolium chloride</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><topic>Vertebrates: endocrinology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Osmond, Jessica M</creatorcontrib><creatorcontrib>Dorrance, Anne M</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Endocrinology (Philadelphia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Osmond, Jessica M</au><au>Dorrance, Anne M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>11β-Hydroxysteroid Dehydrogenase Type II Inhibition Causes Cerebrovascular Remodeling and Increases Infarct Size after Cerebral Ischemia</atitle><jtitle>Endocrinology (Philadelphia)</jtitle><date>2009-02-01</date><risdate>2009</risdate><volume>150</volume><issue>2</issue><spage>713</spage><epage>719</epage><pages>713-719</pages><issn>0013-7227</issn><eissn>1945-7170</eissn><coden>ENDOAO</coden><abstract>Direct mineralocorticoid receptor (MR) activation with deoxycorticosterone acetate has deleterious effects on the cerebral vasculature. Inhibition of 11β-hydroxysteroid dehydrogenase type II (11βHSD2) mimics the detrimental effects of elevated mineralocorticoids in the heart, but the effect of enzyme inactivation on the cerebral vasculature is unknown. Therefore, we hypothesized that systemic 11βHSD2 inhibition with carbenoxolone (CBX) would cause remodeling of the middle cerebral artery (MCA) and increase the damage caused by cerebral ischemia. Six-week-old male Sprague Dawley rats were divided into control and CBX (2.5 mg/d) + 0.9% NaCl treated. After 4 wk treatment, rats were used to assess either structure and reactivity of the MCA or the response to cerebral ischemia using the MCA occlusion technique. Cerebral damage was assessed by 2,3,5-triphenyltetrazolium chloride staining and expressed as a percentage of the hemisphere infarcted. CBX treatment increased systolic blood pressure (153.2 ± 7.3 vs. 122.1 ± 4.4 mm Hg; P &lt; 0.05) compared with control rats. MCAs from CBX treated rats were smaller and stiffer than control MCAs over a range of intralumenal pressures, indicating inward remodeling of the vessel. CBX treatment significantly increased ischemic cerebral infarct size compared with control rats (27.1 ± 5.4% vs. 14.8 ± 4.2%; P &lt; 0.05). These data indicate that inhibition of 11βHSD2, and, thus, disproportionate glucocorticoid activation of the MR, results in remodeling of the MCA and worsens the outcome of cerebral ischemia, further underscoring the importance of understanding the mechanism by which MR activation leads to cerebrovascular disease. 11β-Hydroxysteroid dehydrogenase inhibition increases blood pressure, altering cerebral vessel structure in a manner that increases the damaged caused by focal cerebral ischemia in rats.</abstract><cop>Chevy Chase, MD</cop><pub>Endocrine Society</pub><pmid>18845645</pmid><doi>10.1210/en.2008-0808</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0013-7227
ispartof Endocrinology (Philadelphia), 2009-02, Vol.150 (2), p.713-719
issn 0013-7227
1945-7170
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2646544
source Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)
subjects 11β-Hydroxysteroid dehydrogenase
Acetic acid
Biological and medical sciences
Blood pressure
Cerebral blood flow
Cerebral infarction
Cerebrovascular diseases
Cerebrum
Damage assessment
Dehydrogenase
Dehydrogenases
Fundamental and applied biological sciences. Psychology
Glucocorticoids
Hydroxysteroids
Inactivation
Ischemia
Medical sciences
Mineralocorticoid receptors
Neurology
Occlusion
Sodium chloride
Triphenyltetrazolium chloride
Vascular diseases and vascular malformations of the nervous system
Vertebrates: endocrinology
title 11β-Hydroxysteroid Dehydrogenase Type II Inhibition Causes Cerebrovascular Remodeling and Increases Infarct Size after Cerebral Ischemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A16%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=11%CE%B2-Hydroxysteroid%20Dehydrogenase%20Type%20II%20Inhibition%20Causes%20Cerebrovascular%20Remodeling%20and%20Increases%20Infarct%20Size%20after%20Cerebral%20Ischemia&rft.jtitle=Endocrinology%20(Philadelphia)&rft.au=Osmond,%20Jessica%20M&rft.date=2009-02-01&rft.volume=150&rft.issue=2&rft.spage=713&rft.epage=719&rft.pages=713-719&rft.issn=0013-7227&rft.eissn=1945-7170&rft.coden=ENDOAO&rft_id=info:doi/10.1210/en.2008-0808&rft_dat=%3Cproquest_pubme%3E3130598664%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c392t-47eeb4f550c3642af0881d1befeb1b27d943c49474599c92327ccd29203b3acd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3130598664&rft_id=info:pmid/18845645&rft_oup_id=10.1210/en.2008-0808&rfr_iscdi=true